Clinical Trial

Ticagrelor With Low-dose Versus Regular Aspirin in Patients With Acute Coronary Syndrome (ACS) at High-Risk for Ischemia After Percutaneous Coronary Intervention

Study acronym: LD-ASPIRIN
Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated June 18, 2024 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
The present study is aimed to compare the safety and efficacy of Ticagrelor with low-dose Aspirin versus standard dual anti-platelet therapy (DAPT) in patients with acute coronary syndrome (ACS) at high risk for ischemic events after percutaneous coronary intervention (PCI) and stent implantation.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2020-01-22.
Status change: Not Yet Recruiting → Recruiting 2024-06-15
Trial Details
NCT Number NCT04240834
Lead Sponsor Fu Wai Hospital, Beijing, China
Conditions Acute Coronary Syndrome, Interventional Cardiology
Enrollment 1,220 participants
Start Date 2021-02-01
Primary Completion 2025-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2024-06-18